Turbine, founded in 2016 by Kristof Szalay, Ph.D., Daniel Veres, M.D., Ph.D., develops an AI-based platform that simulates tumor cell behavior in patients to understand the complex mechanisms driving the disease.
Simulations can reveal the right modality and combination approach to treat even the most resistant cancers.
Reaching a new height, Turbine has raised €20 million in a series A funding to develop programs targeting DNA damage repair. The round was led by Mercia and MSD Global Health Innovation (GHI) Fund.
Hungarian-founded biotech startup enables to select the right preclinical models, as well as the right patients to confirm the predicted mechanisms, targets, biomarkers, and combinations.
“The idea sprung from our frustration that conventional experiments frequently lead to expensive and time-consuming drug development failures.
“We’re poised to demonstrate that simulations not only reveal new ways of treating cancer, but increase the likelihood of success at every single step of the drug development process,” Szabolcs Nagy, chief executive officer and co-founder of Turbine said.
Turbine will use the investment to drive its next generation, potential first-in-class programs targeting DNA damage repair, and to transform key aspects of the oncology drug discovery and development process.
